Does NSAID exacerbated respiratory disease (N-ERD) accompanying severe asthma affect biological treatment response? Efficacy of omalizumab and mepolizumab in N-ERD

INTRODUCTION: Non-steroidal anti-inflammatory drug (NSAID)-exacerbated respiratory disease (N-ERD) accompanies severe asthma in about 15% of the patients and may adversely affect the prognosis. Omalizumab and mepolizumab are biologics used in patients with severe asthma. The objective of this study...

Descripción completa

Detalles Bibliográficos
Autores principales: Tepetam, Fatma Merve, Özden, Şeyma, Kılıç, Fatma Kübra, Örçen, Cihan, Yakut, Tuğçe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: World Allergy Organization 2023
Materias:
Full Length Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10522979/
https://www.ncbi.nlm.nih.gov/pubmed/37771938
http://dx.doi.org/10.1016/j.waojou.2023.100817

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10522979/
https://www.ncbi.nlm.nih.gov/pubmed/37771938
http://dx.doi.org/10.1016/j.waojou.2023.100817

Ejemplares similares